FAP and ovarian carcinoma: The current results suggest that targeting FAP could have no pleiotropic anti-tumor effects, and anti-FAP therapy would be an ineffective treatment for ovarian cancer, although contrasting data suggested that FAP may be a candidate molecule for molecular targeting therapy [26].